1. 1) Bers DM, Despa S. Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts. J. Pharmacol. Sci., 100, 315–322 (2006).
2. 2) Matsuda T, Arakawa N, Takuma K, Kishida Y, Kawasaki Y, Sakaue M, Takahashi K, Takahashi T, Suzuki T, Ota T, Hamano-Takahashi A, Onishi M, Tanaka Y, Kameo K, Baba A. SEA0400, a novel and selective inhibitor of the Na+–Ca2+ exchanger, attenuates reperfusion injury in the in vitro and in vivo cerebral ischemic models. J. Pharmacol. Exp. Ther., 298, 249–256 (2001).
3. 3) Tanaka H, Nishimaru K, Aikawa T, Hirayama W, Tanaka Y, Shigenobu K. Effect of SEA0400, a novel inhibitor of sodium–calcium exchanger, on myocardial ionic currents. Br. J. Pharmacol., 135, 1096–1100 (2002).
4. 4) Matsuda T, Koyama Y, Baba A. Functional proteins involved in regulation of intracellular Ca2+ for drug development: pharmacology of SEA0400, a specific inhibitor of the Na+–Ca2+ exchanger. J. Pharmacol. Sci., 97, 339–343 (2005).
5. 5) Tanaka H, Namekata I, Takeda K, Kazama A, Shimizu Y, Moriwaki R, Hirayama W, Sato A, Kawanishi T, Shigenobu K. Unique excitation-contraction characteristics of mouse myocardium as revealed by SEA0400, a specific inhibitor of Na+–Ca2+ exchanger. Naunyn Schmiedebergs Arch. Pharmacol., 371, 526–534 (2005).